Spots Global Cancer Trial Database for platinum
Every month we try and update this database with for platinum cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | NCT06256237 | Limited Stage S... | JS004 Toripalimab surgery Etoposide Platinum | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | NCT00116610 | Small Cell Lung... | picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00484666 | Ovarian Cancer | 18 Years - | Carilion Clinic | ||
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | NCT03607539 | Lung Neoplasms | Sintilimab Pemetrexed Platinum Placebos | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients | NCT03731442 | Esophageal Canc... | Involved field ... Elective field ... Paclitaxel Platinum PEG-rhG-CSF | 16 Years - 70 Years | ChineseAMS | |
| Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | NCT05624099 | Esophageal Neop... Esophageal Dise... Digestive Syste... | camrelizumab Paclitaxel drug... Platinum drug Radiation | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer | NCT01348009 | Gastric Carcino... | Tesetaxel-capec... | 20 Years - | Genta Incorporated | |
| A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | NCT04420884 | Solid Neoplasms | Dazostinag Pembrolizumab Platinum 5-fluorouracil | 18 Years - | Takeda | |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | NCT03404960 | Pancreatic Aden... | Niraparib + Niv... Niraparib + Ipi... | 18 Years - | University of Pennsylvania | |
| Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer | NCT02043288 | Pancreatic Neop... | NC-6004 Gemcitabine | 20 Years - 80 Years | Orient Europharma Co., Ltd. | |
| A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer | NCT01967875 | Stomach Neoplas... | Capecitabine+Ci... Docetaxel+Capec... | 18 Years - 65 Years | China Medical University, China | |
| Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum | NCT01426126 | Bladder Cancer Ureter Cancer | Genexol PM | 18 Years - | Asan Medical Center | |
| Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | NCT06128460 | Cervical Cancer | Zimberelimab Platinum radiotherapy | 18 Years - 70 Years | Obstetrics & Gynecology Hospital of Fudan University | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | NCT03567642 | Lung Cancer | Osimertinib Platinum Etoposide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | NCT00465725 | Bladder Cancer Breast Cancer Colorectal Canc... Gastrointestina... Head and Neck C... Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer | Picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer | NCT02489409 | Breast Neoplasm... | EndostarTM Inje... Gemcitabine Navelbine Platinum Xeloda Tablets: | 18 Years - 70 Years | Xinjiang Medical University | |
| Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer | NCT03154242 | Carcinoma, Non-... | 18 Years - | Ain Shams University | ||
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | NCT06211036 | Extensive-Stage... Small-Cell Lung... | Tarlatamab Durvalumab | 18 Years - 99 Years | Amgen | |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | NCT05312671 | Small Cell Neur... Bladder Cancer Urothelial Carc... | Atezolizumab Carboplatin Cisplatin Etoposide Cystectomy | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | NCT00394433 | Esophageal Canc... Stomach Cancer | Bevacizumab Docetaxel Cisplatin Irinotecan | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer | NCT01967875 | Stomach Neoplas... | Capecitabine+Ci... Docetaxel+Capec... | 18 Years - 65 Years | China Medical University, China | |
| A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | NCT03808857 | Cervical Cancer | GB226 | 18 Years - | Genor Biopharma Co., Ltd. | |
| Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | NCT00394433 | Esophageal Canc... Stomach Cancer | Bevacizumab Docetaxel Cisplatin Irinotecan | 18 Years - | Dana-Farber Cancer Institute | |
| A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | NCT03808857 | Cervical Cancer | GB226 | 18 Years - | Genor Biopharma Co., Ltd. | |
| A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer | NCT01967875 | Stomach Neoplas... | Capecitabine+Ci... Docetaxel+Capec... | 18 Years - 65 Years | China Medical University, China | |
| A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | NCT04453930 | Small Cell Lung... | Camrelizumab，an... Platinum Irinotecan Apatinib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | NCT03639935 | Biliary Tract C... | Rucaparib Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | NCT02766582 | Ovarian Cancer | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | Medical College of Wisconsin | |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | NCT05844150 | SCLC | PM8002 Platinum Atezolizumab Etoposide | 18 Years - | Biotheus Inc. | |
| Trial of BMS-986012 in Combination With Platinum and Etoposide | NCT02815592 | Small Cell Lung... | BMS-986012 Cisplatin Etoposide Platinum Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | NCT00465725 | Bladder Cancer Breast Cancer Colorectal Canc... Gastrointestina... Head and Neck C... Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer | Picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | NCT03607539 | Lung Neoplasms | Sintilimab Pemetrexed Platinum Placebos | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Trial of BMS-986012 in Combination With Platinum and Etoposide | NCT02815592 | Small Cell Lung... | BMS-986012 Cisplatin Etoposide Platinum Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) | NCT04765059 | Non-small Cell ... | Osimertinib (AZ... Placebo for osi... | 18 Years - 130 Years | AstraZeneca | |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | NCT03639935 | Biliary Tract C... | Rucaparib Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Randomized Gefitinib Trial | NCT00807066 | Non Small Cell ... | Gefitinib Platinum | 18 Years - | Fondazione Humanitas per la Ricerca | |
| A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) | NCT04765059 | Non-small Cell ... | Osimertinib (AZ... Placebo for osi... | 18 Years - 130 Years | AstraZeneca | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | NCT05872412 | Triple Negative... | Doxorubicin Cyclophosphamid... Paclitaxel Carboplatin | 18 Years - | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | |
| Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer | NCT01276769 | Triple Negative... | Paclitaxel plus... Paclitaxel and ... | 18 Years - 70 Years | ChineseAMS | |
| Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | NCT05624099 | Esophageal Neop... Esophageal Dise... Digestive Syste... | camrelizumab Paclitaxel drug... Platinum drug Radiation | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | NCT06211036 | Extensive-Stage... Small-Cell Lung... | Tarlatamab Durvalumab | 18 Years - 99 Years | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
